non-small cell lung
Showing 1 - 25 of >10,000
Double-dose Furmonertinib in Treatment of Slow
Not yet recruiting
- Non Small Cell Lung Cancer
- +3 more
- (no location specified)
Oct 31, 2023
Specific Protein Overexpression in Adult Non-Small Cell Lung
Not yet recruiting
- Non Small Cell Lung Cancer
- (no location specified)
Sep 29, 2023
NSCLC, EGFR Gene Mutation, EGFR-TKI Resistant Mutation Trial (Nintedanib, gefitinib, erlotinib, afatinib)
Not yet recruiting
- Non-small Cell Lung Cancer
- +2 more
- Nintedanib, gefitinib, erlotinib, afatinib
- (no location specified)
Oct 2, 2023
Stage II-IIIB(N2) NSCLC Trial in Shanghai (TQB2450, Carboplatin, Pemetrexed)
Not yet recruiting
- Stage II-IIIB(N2) Non-small Cell Lung Cancer
- TQB2450
- +4 more
-
Shanghai, Shanghai, ChinaShanghai Pulmonary Hospital
Oct 26, 2023
NSCLC Trial in Shanghai
Not yet recruiting
- Non-small Cell Lung Cancer
-
Shanghai, Shanghai, ChinaShanghai Pulmonary Hospital
Jul 20, 2023
NSCLC, Neoadjuvant Therapy, Radiotherapy Trial in Yangzhou (drug, radiation, other)
Recruiting
- Non-small Cell Lung Cancer
- +3 more
- Toripalimab
- +2 more
-
Yangzhou, Jiangsu, ChinaPeople's hospital of northern jiangsu
Sep 26, 2023
NSCLC Trial (Tirelizumab;Chemotherapy monotherapy)
Not yet recruiting
- Non-small Cell Lung Cancer
- Tirelizumab；Chemotherapy monotherapy
- (no location specified)
Jul 27, 2023
NSCLC Trial in Iowa City (Durvalumab, Pharmacological ascorbate, Surgery (SOC))
Not yet recruiting
- Non-small Cell Lung Cancer
- Durvalumab
- +2 more
-
Iowa City, IowaUniversity of Iowa
Oct 10, 2023
NSCLC With Mutation in Epidermal Growth Factor Receptor Trial (Osimertinib, Aspirin)
Not yet recruiting
- Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor
- (no location specified)
Aug 27, 2023
Stage IB Non-small Cell Lung Cancer
Completed
- Stage IB Non-Small Cell Lung Carcinoma
-
Shanghai, China180 Fenglin Road
Jul 29, 2023
Non Small Cell Lung Cancer Metastatic Trial (MRI)
Not yet recruiting
- Non Small Cell Lung Cancer Metastatic
- MRI
- (no location specified)
May 16, 2023
Identify Resected Non-small-cell Lung Cancer With High Risk of
Recruiting
- Non-small Cell Lung Cancer Stage IIIA
- Resected non small cell lung cancer
-
Toulouse, FranceJulien MAZIERES
Feb 8, 2023
Iruplinalkib in Treatment of ALK-Positive Non-Small Cell Lung
Recruiting
- Non-small Cell Lung Cancer (NSCLC)
-
Jinan, Shandong, ChinaShandong Cancer Hospital and Institute
Aug 8, 2023
NSCLC Trial in Beijing
Recruiting
- NSCLC
-
Beijing, ChinaYuyan Wang
Oct 10, 2023
NSCLC Trial in Wuhan (Cadonilimab, Pemetrexed, Carboplatin)
Recruiting
- Carcinoma, Non-Small-Cell Lung
- Cadonilimab
- +2 more
-
Wuhan, Hubei, ChinaQian Chu
Aug 18, 2023
NSCLC Trial in Omaha (PLB1004)
Not yet recruiting
- Non-Small Cell Lung Cancer
-
Omaha, NebraskaNebraska Cancer Specialists
Sep 19, 2023
Untreated Advanced NSCLC Trial in Fuzhou (Recombinant human adenovirus type 5 injection (H101) combined with tirilizumab and
Recruiting
- Untreated Advanced Non-small Cell Lung Cancer
- Recombinant human adenovirus type 5 injection (H101) combined with tirilizumab and platinum-containing two-drug chemotherapy
-
Fuzhou, Fujian, ChinaFujian Cancer Hospital
Nov 13, 2023
NSCLC Trial (Tislelizumab IV, Tislelizumab SC, Histology-Based Chemotherapy Doublet)
Not yet recruiting
- Non-small Cell Lung Cancer
- Tislelizumab IV
- +2 more
- (no location specified)
Oct 25, 2023
NSCLC Trial in Guangzhou (BL-M07D1)
Not yet recruiting
- Non-small Cell Lung Cancer
-
Guangzhou, Guangdong, ChinaSun Yat-sen University Cancer Center
Nov 1, 2023
Examination of Trends in Non-Small Cell Lung Cancer Patients'
Not yet recruiting
- Non-Small Cell Lung Cancer
- (no location specified)
Mar 10, 2023
Integrative Multi-Omics Testing for Immunotherapy Response in
Recruiting
- Lung Cancer
-
Guangzhou, Guangdong, ChinaNanfang hospital
Jun 29, 2023
Advanced NSCLC Trial in Jinan (almonertinib)
Recruiting
- Advanced Non-small Cell Lung Cancer
-
Jinan, Shandong, ChinaDegan Lu
Sep 12, 2023